- Open Access
Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1
© The Author(s). 2017
Received: 28 February 2017
Accepted: 21 August 2017
Published: 25 August 2017
To overcome the hostile hypoxic microenvironment of solid tumors, tumor cells secrete a large number of non-coding RNA-containing exosomes that facilitate tumor development and metastasis. However, the precise mechanisms of tumor cell-derived exosomes during hypoxia are unknown. Here, we aim to clarify whether hypoxia affects tumor growth and progression by transferring long non-coding RNA-urothelial cancer-associated 1 (lncRNA-UCA1) enriched exosomes secreted from bladder cancer cells.
We used bladder cancer 5637 cells with high expression of lncRNA-UCA1 as exosome-generating cells and bladder cancer UMUC2 cells with low expression of lncRNA-UCA1 as recipient cells. Exosomes derived from 5637 cells cultured under normoxic or hypoxic conditions were isolated and identified by transmission electron microscopy, nanoparticle tracking analysis and western blotting analysis. These exosomes were co-cultured with UMUC2 cells to evaluate cell proliferation, migration and invasion. We further investigated the roles of exosomal lncRNA-UCA1 derived from hypoxic 5637 cells by xenograft models. The availability of lncRNA-UCA1 in serum-derived exosomes as a biomarker for bladder cancer was also assessed.
We found that hypoxic exosomes derived from 5637 cells promoted cell proliferation, migration and invasion, and hypoxic exosomal RNAs could be internalized by three bladder cancer cell lines. Importantly, lncRNA-UCA1 was secreted in hypoxic 5637 cell-derived exosomes. Compared with normoxic exosomes, hypoxic exosomes derived from 5637 cells showed the higher expression levels of lncRNA-UCA1. Moreover, Hypoxic exosomal lncRNA-UCA1 could promote tumor growth and progression though epithelial-mesenchymal transition, in vitro and in vivo. In addition, the expression levels of lncRNA-UCA1 in the human serum-derived exosomes of bladder cancer patients were higher than that in the healthy controls.
Together, our results demonstrate that hypoxic bladder cancer cells remodel tumor microenvironment to facilitate tumor growth and development though secreting the oncogenic lncRNA-UCA1-enriched exosomes and exosomal lncRNA-UCA1 in human serum has the possibility as a diagnostic biomarker for bladder cancer.
Intratumoral hypoxia has been widely acknowledged as one of the most fundamental tumor microenvironment stresses for solid tumors, which is unfavorable for the rapid expansion of tumors . In this harsh microenvironment, tumor cells reshape their surrounding microenvironment not only to sustain survival and optimal growth but also to subsequently promote invasion and dissemination . However, the mechanisms of cancer cells remodeling the tumor microenvironment to adapt hypoxia remain unknown. Small extracellular vesicles also known as exosomes can be released by tumor cells to promote tumor progression and metastasis, which represents an important and effective mechanism for improving communication between tumor cells and their microenvironment [3, 4]. Therefore, it is clear that a better comprehension of the microenvironment changes induced by tumor cell-derived exosomes could be useful for targeting both primary tumor growth and metastasis.
Tumor cell-derived exosomes as signal transporters modulate local and systemic tumor microenvironment by horizontal transferring bioactive factors such as proteins, RNAs, and DNAs . Notably, RNAs are reported to be the predominant molecular cargos of tumor cell-derived exosomes, and many species of non-coding RNAs including microRNAs (miRNAs) , circular RNAs  and long non-coding RNAs (lncRNAs)  are also enriched in these exosomes, which can reflect the dysregulated non-coding RNAs profiles in tumor cells . Furthermore, these functional non-coding RNAs delivered by exosomes to a recipient cell can regulate gene expression to promote primary tumor growth and local invasion and to favour the formation of premetastatic or metastatic niches [10–12]. Accumulating evidence has highlighted the exosomal non-coding RNAs can enter bloodstream or other body fluids, and these plasma/serum-derived or urinary-derived exosomal non-coding RNAs may serve as the early diagnostic or prognostic non-invasive biomarker for human cancers [13, 14]. To adapt hypoxic microenvironment, tumor cells can also stimulate exosomal secretion or regulate the content of exosomes, which accelerate tumor metastasis to more appropriate environment [15–17]. The hypoxic tumor cell-derived exosomal non-coding RNAs have also been reported to play significant roles in facilitating angiogenesis and dissemination [18, 19].
Urothelial cancer-associated 1 (UCA1) is first reported to be an oncogenic lncRNA which is highly overexpressed in bladder cancer tissues and promotes bladder cancer cell proliferation by regulating several different downstream targets or pathways, including cAMP response element-binding protein (CREB), chromatin remodeling factor (BRG1), phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and Wnt pathways [20–25]. Moreover, lncRNA-UCA1 can also promote EMT, migration, and invasion of bladder cancer cells though the hsa-miR-145–zinc finger E-box binding homeobox 1⁄2 (ZEB1⁄2)–fascin homologue 1 (FSCN1) pathway . Importantly, UCA1 has also been identified as a hypoxia-responsive lncRNA that can promote the proliferation, migration, and invasion of bladder cancer cells under hypoxia . However, the precise mechanism by which lncRNA-UCA1 modulates bladder tumor growth and progression under hypoxia has not been completely elucidated. Additionally, a recent study reported that lncRNA-UCA1 can be packed in exosomes secreted from breast cancer cells . Therefore, from the results of these studies, we speculated that hypoxia reshapes the tumor microenvironment to enhance bladder tumor growth and progression by transferring exosomal lncRNA-UCA1.
Here, we demonstrated that hypoxic exosomes derived from bladder cancer cells promote cell proliferation, migration and invasion. Remarkably, hypoxia enhances exosome-mediated transferring of lncRNA-UCA1 and hypoxic exosomal lncRNA-UCA1 enhances tumor growth in vitro and in vivo. Furthermore, hypoxic exosomal lncRNA-UCA1 promotes tumor progression though epithelial-mesenchymal transition (EMT). In addition, the expression levels of exosomal lncRNA-UCA1 are higher in the bladder cancer patients’ serum than in healthy donors’ serum. Therefore, our studies elucidated the mechanism that hypoxia promotes bladder tumor growth and development and provided a potential diagnostic biomarker for bladder cancer.
Identification of exosomes derived from bladder cancer cells cultured under normoxic and hypoxic conditions
Hypoxic bladder cancer cell-derived exosomes promote bladder cancer cell proliferation, migration and invasion
Hypoxia enhances exosome-mediated transferring of lncRNA-UCA1 into bladder cancer cells
To further evaluate whether exosomal lncRNA-UCA1 was internalized by bladder cancer cells, we have also evaluated the relative UCA1 expression levels in different bladder cancer cell lines by RT-PCR and qRT-PCR. 5637 cells expressed relatively higher levels of UCA1, whereas UMUC2 cells expressed relatively lower levels of UCA1. Moreover, the expression levels of UCA1 could rarely be detected in UMUC2 cells by RT-PCR and qRT-PCR (Additional file 1: Figure S1a and b). Thus, UMUC2 cells were treated with different concentrations of 5637 cell-derived normoxic or hypoxic exosomes. The expressing levels of lncRNA-UCA1 in UMUC2 cells were upregulated in a dose-dependent manner compared with control cells treated with PBS (Fig. 4f and g). To clarify whether the expression levels of lncRNA-UCA1 in exosomes were induced by hypoxia, we detected intracellular or exosomal lncRNA-UCA1 expression levels by qRT-PCR. We found that hypoxia could induce the upregulation of lncRNA-UCA1 not only in bladder cancer cells but also in bladder cancer cell-derived exosomes (Fig. 4h and i). Collectively, these data indicate UCA1 may act as not only an intracellular hypoxia-responsive lncRNA but also an exosomal hypoxia-responsive lncRNA in bladder cancer.
Hypoxic exosomal lncRNA-UCA1 promotes bladder cancer cell proliferation, migration and invasion
Hypoxic exosomal lncRNA-UCA1 facilitates bladder tumor growth
Hypoxic exosomal lncRNA-UCA1 promotes tumor progression though EMT
To elucidate the underlying mechanism of exosomal lncRNA-UCA1-mediated tumor growth and progression, 5637 cells were treated with hypoxic lncRNA-UCA1 shRNA exosomes or hypoxic control shRNA exosomes. As shown in Fig. 6f, the expressing levels of lncRNA-UCA1 in 5637 cells treated with hypoxic lncRNA-UCA1 shRNA exosomes were significantly downregulated. Western blotting analysis revealed the decreased expression levels of the proliferation marker Ki67 in hypoxic lncRNA-UCA1-depressing exosomes treated group (Fig. 6g). Furthermore, hypoxic lncRNA-UCA1-depressing exosomes also significantly increased the expression levels of E-cadherin, while markedly decreasing the expression levels of vimentin and MMP9 in vitro or in vivo (Fig. 6g and h). These findings indicate that hypoxic exosomal lncRNA-UCA1 promotes bladder tumor progression though EMT.
Circulating exosomal lncRNA-UCA1 might act as a potential diagnostic biomarker for bladder cancer
Hypoxic microenvironments of most prevalent malignancies exist in the interior away from their blood vessels. In these regions, cancer cells remodel their unfavorable microenvironment for tumor growth and metastatic dissemination, which usually cause resistance to cancer therapy . Hence, it is necessary to explore the precise mechanism that how cancer cells reshape their surrounding microenvironment under hypoxic conditions. Several studies have described that exosomal proteins and miRNAs derived from hypoxic tumor cells are transferred or delivered to modulate biological function and cell signaling of recipient cells [19, 31, 32]. Apart from unique proteins or miRNAs, it is of interest to further investigate if hypoxia might promote tumor progression through transferring other species of exosomal non-coding RNA. In this study, we found that hypoxic exosome-mediated bladder cancer cell proliferation, migration and invasion are dependent on lncRNA-UCA1. Hypoxia enhances exosome-mediated shuttling of lncRNA-UCA1 into bladder cancer cells and hypoxic exosomal lncRNA-UCA1 also promotes tumor growth and progression in vitro and in vivo. Therefore, our data suggest that oncogenic lncRNA-UCA1 is an important content of hypoxic bladder cancer cell-derived exosomes to promote primary tumor growth and progression.
Hypoxia can induce the expression of several cancer-related lncRNAs in cancer cells [35–37]. Importantly, our previous study found that lncRNA-UCA1 is also a hypoxia-responsive lncRNA . Here, we uncovered that hypoxia induces the upregulation of lncRNA-UCA1 not only in bladder cancer cells but also in bladder cancer cell-derived exosomes. Our findings indicate that the mechanism of hypoxia-mediated shuttling of lncRNA-UCA1 into bladder cancer exosomes may depend on the upregulation of intracellular lncRNA-UCA1 induced by hypoxia. Therefore, hypoxia is verified to regulate the content of exosomes derived from bladder cancer cells.
Non-coding RNAs are encapsulated in exosomes to protect RNA from degradation by ribonuclease and hence these exosomal non-coding RNAs are particularly stable in body fluids [38, 39]. Here, we validated that exosomes provided a protective membrane for lncRNA-UCA1 against RNase degradation. Remarkably, some lncRNAs have been described to exert their biological functions though long RNA forms or being processed into shorter RNA forms . Therefore, the integrity of lncRNA-UCA1 in tumor cell-derived exosomes needs to be identified. Our study indicated that the full-length form of lncRNA-UCA1 (~1.4 kb) is detected in bladder cancer cell-derived normoxic and hypoxic exosomes. This ~1.4 kb transcript is the major form of lncRNA-UCA1 in human cancer cells and it can promote tumor growth and progression . Our results suggest that the ~1.4 kb transcript of lncRNA-UCA1 plays an oncogenic role not only in bladder cancer cells but also in extracellular milieu.
When exosomes released from tumor cells, these may enter the circulation. To date, exosomal non-coding RNAs have been detected in plasma, serum, urine, and other body fluids . The expression levels of some exosomal lncRNAs correlate with the clinical classification and prognosis of human cancers and may be used for cancer biomarkers [42–44]. Our results were consistent with previous reports showing that exosomal lncRNA-UCA1 levels in the serum of bladder cancer patients are higher when compared to normal subjects. These results provide novel evidence that circulating exosomal lncRNA-UCA1 may serve as a potential biomarker for bladder cancer diagnosis. Nevertheless, the correlation between exosomal lncRNA-UCA1 expression in serum and tumor grade, stage and poor prognosis of bladder cancer patients remains unknown, and the diagnostic or prognostic values of circulating exosomal lncRNA-UCA1 in bladder cancers still needs further investigation in a large-scale clinical study.
In summary, our study demonstrated that hypoxia reshapes tumor microenvironment to promote bladder tumor growth and aggressiveness though releasing lncRNA-UCA1-containing exosomes and exosomal lncRNA-UCA1 in human serum may be considered as a potential diagnostic biomarker for bladder cancer.
Cell culture and hypoxia exposure
Human bladder cancer 5637, UMUC2 and T24 cells were grown in RPMI-1640 medium (Gibco, Grand Island, NY, USA) with 10% bovine calf serum and maintained at 37 °C under a humidified 5% CO2 atmosphere. For hypoxic experiments, hypoxia was achieved using an oxygen control incubator (Heal Force, Shanghai, China), which was flushed with a mixture of 1% O2, 94% N2, and 5% CO2. The cells were cultured for 24–72 h under hypoxic conditions.
Human serum samples were collected from the First Affiliated Hospital of Xi’an Jiaotong University (Xi’an, Shaanxi, P.R. China) and obtained informed consent from 30 patients diagnosed bladder cancer and 30 healthy volunteers without any malignancy. The study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University. The clinical pathological characteristics of bladder cancer patients are listed in Additional file 5: Table S1.
Isolation of bladder cancer cell-derived exosomes
Bladder cancer 5637 cells were cultured for 48–72 h in advanced RPMI-1640 medium (Gibco) without supplements under normoxic or hypoxic conditions. Exosomes were isolated from the supernatant of 5637 cells by differential centrifugations as previously described . The media were harvested and centrifuged at 300×g for 10 min at 4 °C. The supernatant was further centrifuged at 16,500×g for 20 min at 4 °C and filtered through a 0.22 μm filter. Exosomes were then pelleted by ultracentrifugation at 120,000×g for 70 min at 4 °C. Exosome pellets were resuspended in 0.2 μm-filtered PBS.
Isolation of human serum-derived exosomes
Exosomes were isolated from the human serum samples by ExoQuick solution according to the manufacturer’s instructions (System Biosciences, SBI, Mountain View, CA). Briefly, serum samples were centrifuged at 3000×g for 15 min at 4 °C, and the serum samples (250 μl) were mixed with ExoQuick solution (63 μl). The mixtures were then refrigerated at 4 °C overnight and centrifuged at 1500×g for 30 min at 4 °C. Exosome pellets were resuspended in 0.2 μm-filtered PBS.
Transmission electron microscopy
Exosomes were adsorbed to a 400 mesh carbon-coated copper grids and stained with phosphotungstic acid solution. Morphologies of the samples were observed by a JEOL JEM-100SX transmission electron microscope (JEOL Ltd., Tokyo, Japan).
Nanoparticle tracking analysis
The size distribution of exosomes was determined using a Delsa Nano Analyzer (DelsaNano, Beckman Coulter, Brea, CA, USA). The capture settings and analysis settings were performed manually according to the manufacturer’s instructions.
Quantitative real-time PCR
Exosomes were incubated with RNase A (Takara, Dalian, China, final concentration of 10 μg/ml) at 37 °C for 10 min followed by addition of RNase inhibitor (Takara, final concentration of 1 U/μl). Cellular and exosomal RNAs were isolated using the TRIzol reagent (Invitrogen, Life Technologies, Carlsbad, CA, USA). First-strand cDNA was synthesized with random primers using a PrimeScript™ RT reagent Kit with gDNA Eraser (Takara). Quantitative real-time PCR was carried out using a FastStart Essential DNA Green Master (Roche, Nutley, NJ, USA) on a CFX96 real-time PCR System (Bio-Rad, Hercules, CA, USA), and the results were normalized with ATCB (β-actin) or GAPDH as an internal control. Primers are listed in Additional file 6: Table S2.
Western blotting analysis
Exosomes or cells were lysed in RIPA buffer containing a complete protease inhibitor tablet (Roche). The protein concentration of lysates was normalized according to Bradford relative protein quantification and proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were incubated with CD63, E-cadherin, Ki67, MMP9, TSG101 (Abcam, Hong Kong, China), β-actin, Hsp70, Hsp90, Vimentin (Cell Signaling Technology, CST, Danvers, MA, USA) primary antibodies. Protein expression was assessed by ECL chemiluminescent regents and the intensity of the protein bands was quantified by densitometry using ImageJ software (National Institutes of Health).
Fluorescent dye -labelled exosomal RNAs
Exosomal RNAs were labeled with Exo-GLOW™ kits (SBI) according to the manufacturer’s instructions. Exosomes were stained at 37 °C for 10 min in 1 × PBS containing 10 × Exo-Red dye and bladder cancer cells were incubated with the labeled exosomes at 37 °C for 6–24 h. Images were collected with a Nikon Eclipse Ti-S fluorescence microscope (Nikon, Tokyo, Japan).
Knockdown experiment of exosomal lncRNA-UCA1
For depletion of lncRNA-UCA1, 5637 cells were stable transfected with pRNAT-U6.1⁄UCA1 shRNA or pRNAT-U6.1⁄control shRNA plasmid. The following day, 5637 cells were cultured in advanced 1640 medium under hypoxic conditions for 24–48 h. The exosomes derived from 5637 cells were purified as described previously.
Cell proliferation assay
Cell proliferation assay was carried out using the Cell Count Kit (7Sea Pharmatech Co., Ltd., Shanghai, China). Briefly, UMUC2 cells (4000 cells/well) were seeded in 96-well plates and incubated with exosomes (5 μg/ml) for a total of 72 h. Absorbance was measured at 450 nm using a PerkinElmer Enspire plate reader (PerkinElmer, Waltham, MA, USA).
Migration and invasion assays
The invasion assay was carried out using 24-well Millicell chambers that were coated with Matrigel (BD Biosciences, San Jose, CA, USA). The migration assay was carried out in a similar fashion without the Matrigel coating. Cells were seeded in serum-free RPMI-1640 to the top chamber. Exosomes (10 μg/ml each well) were added to the bottom chambers and serum-free advanced 1640 medium with PBS as the control. After 24 h of incubation, UMUC2 cells on the upper membrane surface were wiped off using a cotton swab and the lower membrane surface was fixed with methanol, stained with crystal violet, and counted in five random fields.
Five-week-old female athymic nude mice were purchased from the Laboratory Animal Center of Xi’an Jiaotong University (Xi’an, Shaanxi, P.R. China). The 5637 cells (5 × 106 cells per mouse) suspended in 200 μl of PBS were injected subcutaneously into the right flank of nude mice, and two weeks later, when the nude mice generate tumors with a size of 100 mm3, purified exosomes (10 μg) or PBS were then injected into the center of tumor sites. The tumor size and weight of nude mice were weighed and measured twice a week. After three weeks, the nude mice were sacrificed and their tumors tissues and lymph nodes were determined for histological examination.
Primary tumors were fixed in formalin and embedded in paraffin, and then cut at 4 μm thickness. The sections were incubated with primary antibodies (E-cadherin, HIF-1α, MMP9, Abcam) at 4 °C overnight. After washing with PBS, the sections were then incubated with Poly HRP-conjugated anti-mouse or anti-rabbit IgG for 30 min, followed by DAB. Finally, the sections were counterstained with hematoxylin. The staining intensity of HIF-1α was assessed by two independent pathologists as no staining = 0, weak staining = 1, moderate staining = 2, and strong staining = 3. Tumor cells in five random fields were scored based on the percentage of nuclei with positive staining cells (0–100%). An overall immunohistochemistry score was calculated by multiplying the intensity score with the percentage of positive staining tumor cells.
All statistical analyses were carried out using GraphPad Prism Software (GraphPad Software, Inc., San Diego, CA, USA). Statistical evaluations were determined using Student’s t-test (two-tailed) or Spearman correlation test. P value <0.05 was considered statistically significant. In vitro experiments were replicated at least three times.
This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 81502529, 81301513 and 81372151).
MX, WC, AX, XL contributed to the design of the study. MX, AX, RQW, HC, JJP, HLA performed the experiments. MX, AX, XL contributed to the writing and revision of the manuscript. HP, XW, HLH contributed to the material support of the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12:487–93. doi:10.1038/nrc3298.View ArticlePubMedPubMed CentralGoogle Scholar
- Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16:5928–35. doi:10.1158/1078-0432.CCR-10-1360.View ArticlePubMedPubMed CentralGoogle Scholar
- Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226–32. doi:10.1016/j.cell.2016.01.043.View ArticlePubMedGoogle Scholar
- Rak J. Cancer: organ-seeking vesicles. Nature. 2015;527:312–4. doi:10.1038/nature15642.View ArticlePubMedGoogle Scholar
- Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177–82. doi:10.1038/nature14581.View ArticlePubMedPubMed CentralGoogle Scholar
- Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. Cancer Exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26:707–21. doi:10.1016/j.ccell.2014.09.005.View ArticlePubMedPubMed CentralGoogle Scholar
- Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X, Huang S. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25:981–4. doi:10.1038/cr.2015.82.View ArticlePubMedPubMed CentralGoogle Scholar
- Conigliaro A, Costa V, Lo DA, Saieva L, Buccheri S, Dieli F, Manno M, Raccosta S, Mancone C, Tripodi M, De Leo G, Alessandro R. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer. 2015;14:155. doi:10.1186/s12943-015-0426-x.View ArticlePubMedPubMed CentralGoogle Scholar
- Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WJ, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–6. doi:10.1186/s12943-015-0426-x.View ArticlePubMedPubMed CentralGoogle Scholar
- Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9. doi:10.1038/ncb1596.View ArticlePubMedGoogle Scholar
- Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015;527:100–4. doi:10.1038/nature15376.View ArticlePubMedPubMed CentralGoogle Scholar
- Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, Huang B, Xu X, Zheng J, Cao X. Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 2016;30:243–56. doi:10.1016/j.ccell.2016.06.021.View ArticlePubMedGoogle Scholar
- Li M, Zeringer E, Barta T, Schageman J, Cheng A, Vlassov AV. Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philos Trans R Soc B Biol Sci. 2014;369:20130502. doi:10.1098/rstb.2013.0502.View ArticleGoogle Scholar
- Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–15. doi:10.1016/j.ccr.2014.03.007.View ArticlePubMedPubMed CentralGoogle Scholar
- King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012;12:421. doi:10.1186/1471-2407-12-421.View ArticlePubMedPubMed CentralGoogle Scholar
- Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M, Morgelin M, Bourseau-Guilmain E, Bengzon J, Belting M. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110:7312–7. doi:10.1073/pnas.1220998110.View ArticlePubMedPubMed CentralGoogle Scholar
- Umezu T, Tadokoro H, Azuma K, Yoshizawa S, Ohyashiki K, Ohyashiki JH. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124:3748–57. doi:10.1182/blood-2014-05-576116.View ArticlePubMedPubMed CentralGoogle Scholar
- Tadokoro H, Umezu T, Ohyashiki K, Hirano T, Ohyashiki JH. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem. 2013;288:34343–51. doi:10.1074/jbc.M113.480822.View ArticlePubMedPubMed CentralGoogle Scholar
- Li L, Li C, Wang S, Wang Z, Jiang J, Wang W, Li X, Chen J, Liu K, Li C, Zhu G. Exosomes derived from hypoxic oral squamous cell carcinoma cells deliver miR-21 to normoxic cells to elicit a prometastatic phenotype. Cancer Res. 2016;76:1770–80. doi:10.1158/0008-5472.CAN-15-1625.View ArticlePubMedGoogle Scholar
- Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, Zhang Y, Xin DQ, Na YQ, Chen WF. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res. 2006;12:4851–8. doi:10.1158/1078-0432.CCR-06-0134.View ArticlePubMedGoogle Scholar
- Wang F, Li X, Xie XJ, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582:1919–27. doi:10.1016/j.febslet.2008.05.012.View ArticlePubMedGoogle Scholar
- Yang C, Li X, Wang Y, Zhao L, Chen W. Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene. 2012;496:8–16. doi:10.1016/j.gene.2012.01.012.View ArticlePubMedGoogle Scholar
- Pan J, Li X, Wu W, Xue M, Hou H, Zhai W, Chen W. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 2016;382:64–76. doi:10.1016/j.canlet.2016.08.015.View ArticlePubMedGoogle Scholar
- Wang X, Gong Y, Jin B, Wu C, Yang J, Wang L, Zhang Z, Mao Z. Long non-coding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells. Oncol Rep. 2014;32:1281–90. doi:10.3892/or.2014.3309.PubMedPubMed CentralGoogle Scholar
- Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014;281:1750–8. doi:10.1111/febs.12737.View ArticlePubMedGoogle Scholar
- Xue M, Pang H, Li X, Li H, Pan J, Chen W. Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 2016;107:18–27. doi:10.1111/cas.12844.View ArticlePubMedGoogle Scholar
- Xue M, Li X, Li Z, Chen W. Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1α-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumor Biol. 2014;35:6901–12. doi:10.1007/s13277-014-1925-x.View ArticleGoogle Scholar
- Xu CG, Yang MF, Ren YQ, Wu CH, Wang LQ. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Eur Rev Med Pharm Sci. 2016;20:4362–8.Google Scholar
- Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410. doi:10.1038/nrc3064.View ArticlePubMedGoogle Scholar
- Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605–22. doi:10.1016/j.ccell.2014.10.006.View ArticlePubMedPubMed CentralGoogle Scholar
- Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze SK. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010;9:1085–99. doi:10.1074/mcp.M900381-MCP200.View ArticlePubMedPubMed CentralGoogle Scholar
- Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R, Deep G. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. 2015;54:554–65. doi:10.1002/mc.22124.View ArticlePubMedGoogle Scholar
- Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21:962–8. doi:10.1158/1078-0432.CCR-13-3173.View ArticlePubMedGoogle Scholar
- Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, Zhao M, Li J, Zhang Y, Zhao C, Chen X, Fei K, Zhou C, Hirsch FR. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015;6:23582–93. 10.18632/oncotarget.4361.View ArticlePubMedPubMed CentralGoogle Scholar
- Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1α and lincRNA-p21 modulates the warburg effect. Mol Cell. 2014;53:88–100. doi:10.1016/j.molcel.2013.11.004.View ArticlePubMedGoogle Scholar
- Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, Sun SH. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell. 2013;49:1083–96. doi:10.1016/j.molcel.2013.01.010.View ArticlePubMedGoogle Scholar
- Takahashi K, Yan IK, Haga H, Patel T. Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci. 2014;127:1585–94. doi:10.1242/jcs.141069.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014;3:1–14. doi:10.3402/jev.v3.23743.View ArticleGoogle Scholar
- Le MT, Hamar P, Guo C, Basar E, Perdigao-Henriques R, Balaj L, Lieberman J. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014;124:5109–28. doi:10.1172/JCI75695DS1.View ArticlePubMedPubMed CentralGoogle Scholar
- Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, Gao X, Liu Z, Hou J, Huang J, Sun Y. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49:2949–59. doi:10.1016/j.ejca.2013.04.026.View ArticlePubMedGoogle Scholar
- Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, Feng Y, Liu H, Fei B, Mao Y, Zhou L, Qi X, Huang S, Hua D, Xing C, Huang Z. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep. 2016;6:23892. doi:10.1038/srep23892.View ArticlePubMedPubMed CentralGoogle Scholar
- Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, Chen W, Liu F, Sun W, Li XF, Wang X, Wang Y, Xu ZY, Gao L, Yang Q, Xu B, Li YM, Fang ZY, Xu ZP, Bao Y, Wu DS, Miao X, Sun HY, Sun YH, Wang HY, Wang LH. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29:653–68. doi:10.1016/j.ccell.2016.03.004.View ArticlePubMedGoogle Scholar
- Isin M, Uysaler E, Ozgur E, Koseoglu H, Sanli O, Yucel OB, Gezer U, Dalay N. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. Front Genet. 2015;6:168. doi:10.3389/fgene.2015.00168.PubMedPubMed CentralGoogle Scholar
- Berrondo C, Flax J, Kucherov V, Siebert A, Osinski T, Rosenberg A, Fucile C, Richheimer S, Beckham CJ. Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One. 2016;11:1–21. doi:10.1371/journal.pone.0147236.View ArticleGoogle Scholar
- Lässer C, Eldh M, Lötvall J. Isolation and characterization of RNA-containing exosomes. J Vis Exp. 2012:1–6. doi:10.3791/3037.